Scarica l'app Stockscreener
19.65
0.15%
0.010
Precedente Chiudi:
$19.64
Aprire:
$19.7
Volume 24 ore:
78,113
Relative Volume:
0.20
Capitalizzazione di mercato:
$1.79B
Reddito:
$14.09M
Utile/perdita netta:
$-176.94M
Rapporto P/E:
-7.3728
EPS:
-2.6652
Flusso di cassa netto:
$-141.24M
1 W Prestazione:
-5.61%
1M Prestazione:
+10.38%
6M Prestazione:
+3.96%
1 anno Prestazione:
+102.99%
Intervallo 1D:
$19.41
$19.96
Intervallo di 1 settimana:
$19.21
$21.05
Portata 52W:
$8.90
$26.35
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Confronta NAMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
19.67 | 1.79B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.14 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.61 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
617.51 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
252.22 | 32.63B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.06 | 28.10B | 3.30B | -501.07M | 1.03B | -2.1146 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of "Buy" from Brokerages - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 2.7%What's Next? - MarketBeat
(NAMSW) Pivots Trading Plans and Risk Controls - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Earns “Buy” Rating from Needham & Company LLC - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Jennison Associates LLC - MarketBeat
Needham & Company LLC Reiterates Buy Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results - Yahoo Finance
NewAmsterdam Pharma target raised to $45 on strong trial data By Investing.com - Investing.com Canada
NewAmsterdam Pharma target raised to $45 on strong trial data - Investing.com
Newamsterdam’s obicetrapib combo nails phase III LDL-C endpoints - BioWorld Online
NewAmsterdam Pharma stock falls on trial data (NAMS:NASDAQ) - Seeking Alpha
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH - The Manila Times
NewAmsterdam Pharma stock holds Overweight rating with catalysts ahead in Ph3 topline readouts - Investing.com
Trend Tracker for (NAMSW) - Stock Traders Daily
Frazier Life Sciences Bolsters Leadership with Two Senior Industry Veterans | NAMS Stock News - StockTitan
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - The Manila Times
RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NV - GuruFocus.com
GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions - Simply Wall St
When the Price of (NAMS) Talks, People Listen - Stock Traders Daily
Is NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025? - Insider Monkey
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Lisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Q4 EPS Forecast for NewAmsterdam Pharma Reduced by Analyst - Defense World
William Blair Issues Pessimistic Forecast for NAMS Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for NAMS FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for NAMS FY2024 Earnings - Defense World
Leerink Partnrs Has Strong Estimate for NAMS FY2028 Earnings - Defense World
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $33.80 - Defense World
(NAMSW) Proactive Strategies - Stock Traders Daily
What is Leerink Partnrs' Forecast for NAMS FY2028 Earnings? - MarketBeat
NewAmsterdam Pharma Reports Strong Q3 and Trial Progress - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma - Benzinga
Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends - TipRanks
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts - MarketBeat
NewAmsterdam Pharma Revenue Soars 900%, Reports Strong Q3 Results Ahead of Key Trial Data | NAMS Stock News - StockTitan
abrdn plc Purchases 53,060 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - The Manila Times
[Complimentary] New Amsterdam repositions obicetrapib selectively for advanced cardiovascular disease patients | $NAMS - substack.com
Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN
Piper Sandler maintains consistent target on NASDAQ:NAMS shares - Investing.com
NewAmsterdam Pharma to Restate Prior Financials - Investing.com India
NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):